Intravenous arketamine for treatment-resistant depression: open-label pilot study

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Treatment-resistant depression (TRD) poses a significant challenge in mental healthcare.
• Ketamine has demonstrated rapid antidepressant effects, but its psychotomimetic side effects are a concern.

Purpose of the Study:

• To evaluate the efficacy and safety of arketamine, the R(-)-enantiomer of ketamine, in patients with TRD.
• To assess the potential of arketamine as a novel therapeutic agent for depression.

Main Methods:

• An open-label pilot trial involving seven subjects diagnosed with TRD.
• Administration of a single intravenous infusion of arketamine at a dose of 0.5 mg/kg.
• Assessment of depression severity using the Montgomery-Åsberg Depression Rating Scale (MADRS) 24 hours post-infusion.

Main Results:

• A significant reduction in mean MADRS scores from 30.7 at baseline to 10.4 at 24 hours post-infusion (mean difference of 20.3 points; p < 0.001).
• Dissociative side effects were reported as nearly absent.
• The treatment demonstrated a favorable safety profile.

Conclusions:

• Arketamine may offer rapid-onset and sustained antidepressant effects in humans with TRD.
• The R(-)-enantiomer of ketamine presents a potentially safer alternative to racemic ketamine for depression treatment.
• Further controlled clinical trials are warranted to confirm these preliminary findings and establish optimal treatment protocols.